Researchers led by Lin et al. designed an ACE2 decoy receptor that neutralizes multiple SARS‑CoV‑2 variants, demonstrating activity against mutant spike proteins in preclinical assays. Published in the Journal of Biomedical Science, the work shows engineered soluble ACE2 can retain binding to diverse receptor‑binding domain (RBD) mutations and block viral entry in vitro. The lead finding positions ACE2 decoys as a complementary antiviral strategy to antibodies and vaccines, with potential relevance for rapidly evolving variants that escape neutralizing antibodies.